Inclusion Criteria:

1. Age 18 years or older.

2. EBV-positive or KSHV-associated malignancy, including but not limited to:

- EBV+ Hodgkin lymphoma

- EBV+ non-Hodgkin lymphoma or lymphoproliferative disease

- Primary effusion lymphoma

- Kaposi's sarcoma

- EBV+ gastric cancer

- EBV+ nasopharyngeal cancer

3. Measurable disease (at least one lesion measuring > 2 cm in longest axis).

4. ECOG performance status of 0, 1, or 2.

5. Patients must be able to lie flat for at least 60 minutes and fit on PET-CT scanner.

6. For post-therapy imaging with FIAU-PET, treatment with standard or investigational
agents that can potentially activate herpesvirus TK, including but not limited to
the following. Concurrent radiation therapy is permissible:

- Platinum compounds (for example, cisplatin, carboplatin)

- Anthracyclines (for example, doxorubicin or pegylated doxorubicin)

- Tubulin disrupting agents (for example, vincristine, vinblastine)

- Rituximab

- Gemcitabine

- Cytarabine

- Histone deacetylase inhibitors

- Bortezomib NOTE: Patients who would not receive bortezomib as part of their
usual care may receive a one-time dose of bortezomib for the purpose of imaging
with 124I-FIAU and FIAU-PET-CT.

7. AST and ALT < 3 X upper limit of normal, unless attributed to tumor, obtained within
2 weeks prior to registration.

8. Serum creatinine < 2.0 mg/dL, within 2 weeks prior to registration.

9. In patients who will receive bortezomib for imaging purposes only:

- Total bilirubin < 1.5 X upper limit of normal, obtained within 2 weeks prior to
registration.

- Platelet count > 70,000 / mm3 obtained within 2 weeks prior to registration.

- No pre-existing peripheral neuropathy greater than grade 1.

Exclusion Criteria:

1. End-stage liver disease unrelated to tumor.

2. Known active or chronic hepatitis B or hepatitis C infection.

3. History of iodine hypersensitivity.

4. Chronic renal insufficiency requiring dialysis.

5. Women who are pregnant or breast feeding.

6. Foreseen inability to comply with study requirements.